FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza™ (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adult patients. Vimseltinib is a dual inhibitor of c-FMS and c-Kit. Deciphera is a wholly owned subsidiary of Ono Pharmaceuticals.
Focus Biomolecules can supply Vimseltinib for research applications. For more information, contact us.
